Navigation Links
Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
Date:2/27/2008

SAN DIEGO, Feb. 27 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference on Tuesday, March 4, 2008 at 4:30 p.m. EST (1:30 p.m. PST). The conference is being held at the W Hotel in New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

Additionally, Dr. Worland will participate as a panel member in a discussion of the role of non-nucleoside and nucleoside polymerase inhibitors in the future of HCV therapy at the conference on Wednesday, March 5 at 9:15 a.m.

The corporate presentation on Tuesday, March 4 will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 18, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press releas
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , , CALGARY, Dec. 2 /PRNewswire-F...or the "Company") (TSX:ONC; NASDAQ: ONCY ) announc...nounced unit offering, the underwriters have exerc...ased an additional 637,500 units. Each unit is com...re purchase warrant, and was sold at a price of US...
(Date:12/2/2009)... , , SINGAPORE, Dec. 2 /PRNewswire/...ns on its novel oral JAK2 inhibitor, SB1518, at Th...ng and Exposition in New Orleans. ,, Data will ...e 1 dose-escalation trial of SB1518 detailing its ...ynamic (PK/PD) profile in dose levels ranging from...
(Date:12/2/2009)... , The Scientist, a leadi... ranked Photometrics’ Evolve “Intellig...on’s “Top 10 Innovations of 2009. , ... The Evolve ™ EMCCD camera from Photometr...formance CCD and EMCCD cameras for the life scienc...
(Date:12/1/2009)... , , NEW YORK, Dec. 1 /PRNewswire/ ...search report is available in its catalogue: ,,..., http://www.reportlinker.com/p0164431/Industria...ustrial Enzymes market is an oligopoly with few st... in niche market activities. Keen competition and ...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10
...., May 2 Osteotech, Inc.,(Nasdaq: OSTE ), a lead...,regenerative healing, announced today that its Pl...Reconstruction Program led by Dr. Jeffrey Hollinge...ch was prepared under the,auspices of the New Jers...,Rutgers University, is part of a multi-institutio...
...M) Technology Raising the Bar in Motion Preservati...hnology,Inc., a leader in innovative medical devic...ion of its next generation cervical total disc,rep.... The surgeries were,performed by Drs. Hansen Yuan...ients with degenerative disc disease (DDD) otherwi...
...l/Webcast to be Held Wednesday, May 7, 2008 at 10:...echnologies, Inc. (Nasdaq: EMIS ) will host a con...the first quarter ended March 31, 2008 on,Wednesda...f the conference call can be accessed through the,...The live conference call dial-in,number is: 1-800-...
Other Biology Technology:Osteotech's Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine 2Osteotech's Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine 3Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device 2Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results 2
(Date:12/3/2009)...ntents of this message: , , Preliminary Press...to California Academy of Sciences museum, Attent... NCSWA holiday dinner registration deadline 10 D... News Media Registration Form pre-registration dea..., For important information regarding visas for ...
(Date:12/3/2009)...and Rapids, Mich. (Dec. 3, 2009) Van Andel Rese...precisely how the plant hormone abscisic acid (ABA...ond to environmental stresses such as drought and ...ature , could help engineer crops that thrive in h...al food shortages. The findings could also have i...
(Date:12/3/2009)...rest dwellers must be included in the design of th...void a humanitarian crisis, according to a scienti...in Nature , Dr Simon Lewis argues that at least 5...openhagen, known as REDD (Reducing Emissions from ...forest dwellers directly, and their property right...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Bridges To Recovery a one of a Kind Los Angeles Facility Providing In Patient Psychiatric Treatment Acquires License To Provide Additional Beds 58731 1Bridges To Recovery a one of a Kind Los Angeles Facility Providing In Patient Psychiatric Treatment Acquires License To Provide Additional Beds 58731 2Intercept Pharmaceuticals FXR Agonist INT 747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty 5182 1Intercept Pharmaceuticals FXR Agonist INT 747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty 5182 2Energy autonomous sensors for aircraft 14324 1Energy autonomous sensors for aircraft 14324 2
...er Current , M. Belkin, A. Snezhko, I.S. Aranson, ...ng) , Physicists at Argonne National Laboratory h...er and subjected to an alternating magnetic field ... the flow of the surrounding fluid. Current incarn... long, but the team envisions much smaller version...
...ssful academic entrepreneurs has teamed up with th... and development in membrane biology to pharmaceut...ny Marchington, who turned his spin-out company Ox...rk alongside the Universitys new Centre for Integr...ontracts with industry, based on Leeds world-class...
...EASE , Spinning a new role for CDs and CD player...he hardware used to play these popular audio and v...s a new generation of portable, inexpensive instru...ased testing, scientists in Spain are reporting in...semi-monthly journal. CD technology could be adap...
Other Biology News:Magnetic snakes control fluids, gravity-defying droplets, and solving a dragonfly mystery 2Magnetic snakes control fluids, gravity-defying droplets, and solving a dragonfly mystery 3New partnership offers outsourced R&D in membrane biology 2American Chemical Society's Weekly PressPac -- Sept. 19, 2007 2American Chemical Society's Weekly PressPac -- Sept. 19, 2007 3American Chemical Society's Weekly PressPac -- Sept. 19, 2007 4American Chemical Society's Weekly PressPac -- Sept. 19, 2007 5American Chemical Society's Weekly PressPac -- Sept. 19, 2007 6American Chemical Society's Weekly PressPac -- Sept. 19, 2007 7American Chemical Society's Weekly PressPac -- Sept. 19, 2007 8
Normal Porcine Serum from Equitech-Bio
3-O-Methylguanosine 5-Triphosphate, Sodium from GE Healthcare, formerly Amersham Biosciences
Porcine Serum from Innovative Research
Rat Tissue Array: Brain, heart, kidney, liver, lung, muscle, spleen and stomach, each tissue from 10 female and 10 male, respectively from BioChain
Biology Products: